9 registrations that name thymosin Alpha-1 as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 9 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 9 registrations
RecruitingNCT06821100
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
Phase 1
The Methodist Hospital Research Institute
About 75 people
Started Dec 2, 2024
In plain words A Phase 1 study of thymosin Alpha-1 in people 65 to 100, run by The Methodist Hospital Research Institute. It plans to enroll about 75 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 65 to 100; healthy volunteers accepted. Conditions: Vaccine Response; COVID-19 Vaccine; Immune Response to Covid 19 Vaccination.
Age 65 or greater.
Able and willing to provide informed consent or have consent provided by a legally authorized representative (LAR).
Scheduled for SARS-CoV-2 mRNA vaccination booster dose.
If a male subject, the subject must agree to use barrier contraception (ie, condoms) from Day 1 through 30 days following the last dose of study drug.
The exclusion criteria are on the listing.
What it tests, as registered
Thymalfasin (Thymosin alpha 1, Ta1)
Registered summary
The goal of this research is to learn more about ZADAXIN® (trade name; thymalfasin generic; Ta1 for short) and determine if Ta1 has any benefit in increasing the immune response to the COVID-19 vaccine. Ta1 has been shown to stimulate the immune system to fight infections. This research study will test the safety and possible harms of Ta1 when it is given to people at different dose levels before COVID-19 vaccination.
Where, as registered
1 US site in 1 state.
RecruitingNCT05086614
Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
Phase 3
Fudan University
About 2,500 people
Started Apr 1, 2021
In plain words A Phase 3 study of thymosin Alpha-1 in people 18 to 75, run by Fudan University. It plans to enroll about 2,500 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Stage II Colorectal Cancer; Stage III Colorectal Cancer.
Colorectal cancer receiving radical resection
Pathologically diagnosed with high-risk stage II or stage III
Eastern Cooperative Oncology Group performance status of 0-2
Adequate hepatic, renal, and hematologic function
The exclusion criteria are on the listing.
What it tests, as registered
Thymosin Alpha1
Registered summary
For high-risk stage II and stage III colorectal cancer, even after radical resection and postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and metastasis. Thymosin-alpha 1 is believed to improve immunity and may help promote tumor immunity to reduce the incidence of recurrence and metastasis. This study hopes to verify the effecacy and safety of thymosin-alpha 1 for adjuvant treatment of high-risk stage II and stage III colorectal cancer after radical resection.
Where, as registered
No US site; China (1).
RecruitingNCT07866118
Thymalfasin for Immune Recovery in Adults With Sepsis
No phase
Shanghai Zhongshan Hospital
About 60 people
Starts Oct 6, 2026 (estimated)
In plain words A study of thymosin Alpha-1 in people 18 and older, run by Shanghai Zhongshan Hospital. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Sepsis; Immunosuppression.
Age older than 18 years, of any sex. Sepsis according to Sepsis-3 criteria, defined as documented or suspected infection with an increase in Sequential Organ Failure Assessment (SOFA) score of at least 2 points from baseline.
The exclusion criteria are on the listing.
What it tests, as registered
Thymalfasin (Thymosin alpha 1, Ta1)
Registered summary
Sepsis is a life-threatening illness caused by an abnormal response to infection. Some people with sepsis have reduced immune function, which may make recovery more difficult. This study will examine whether adding thymalfasin, also called thymosin alpha-1, to usual sepsis care improves recovery of immune function. The study will enroll 60 adults with sepsis and evidence of reduced immune function at Zhongshan Hospital, Fudan University. Participants will be assigned by chance to one of two groups. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT06829355
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
Phase 2
Beijing Friendship Hospital
About 52 people
Starts Feb 11, 2025 (estimated)
In plain words A Phase 2 study of thymosin Alpha-1 in people 18 to 75, run by Beijing Friendship Hospital. It plans to enroll about 52 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: MCRC.
Able to sign a written informed consent form (ICF) and able to understand and comply with the requirements of this study Male or female aged 18 to 75 Histologically or cytologically confirmed advanced or metastatic colorectal…
This is a multicenter, open-label, prospective, randomized controlled Phase II clinical study. All eligible subjects will be randomly assigned in a 1:1 ratio to either the triple therapy group or the double therapy group. Triple therapy group: Subjects will receive Thymalfasin in combination with Regorafenib and Tislelizumab until iCPD is achieved per iRECIST (progressive disease (PD) per iRECIST), or until an intolerable toxicity occurs; Double therapy group: Subjects will receive Regorafenib and Tislelizumab until iCPD is achieved per iRECIST (PD per iRECIST), or until an intolerable… The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT06584006
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
Phase 2
The First Affiliated Hospital of Xiamen University
About 50 people
Started Sep 1, 2024
In plain words A Phase 2 study of thymosin Alpha-1 in people 18 and older, run by The First Affiliated Hospital of Xiamen University. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Hematological Malignancy; Lymphocytopenia.
Patients with histologically confirmed myeloid, B lymphocyte, and plasma cell-derived malignant hematological tumors.
Lymphocyte count ≤ 0.8×109/L or CD4+T cell count ≤ 0.35×109/L.
Age ≥ 18 years, both male and female, with an expected survival period of more than 3 months.
Estimated creatinine clearance rate ≥ 30 mL/min.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections; Recombinant Human Interleukin-2 Injections
Registered summary
To evaluate the efficacy and safety of Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections in the treatment of lymphocytopenia in patients with malignant hematological tumors
Where, as registered
No US site; China (1).
RecruitingNCT06461910
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2
Zekuan Xu
About 30 people
Started Jun 14, 2024
In plain words A Phase 2 study of thymosin Alpha-1 in people 18 to 75, run by Zekuan Xu. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Gastric Cancer; Esophagogastric Junction Adenocarcinoma.
Age and Diagnosis:
Stage and Diagnosis Confirmation:
Surgical Assessment:
Previous Treatments:
9 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Serplulimab; thymalfasin; Oxaliplatin; Tegafur
Registered summary
This Phase II clinical study is a prospective, open-label, single-arm trial designed to evaluate the efficacy and safety of combining anti-PD-1 therapy (Serplulimab) with thymalfasin and the SOX chemotherapy regimen as a neoadjuvant treatment for patients with clinical stage III gastric or gastroesophageal junction(GEJ) adenocarcinoma.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07382375
AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
No phase
Nanjing Medical University
About 300 people
Starts Dec 31, 2027 (estimated)
In plain words A study of thymosin Alpha-1 in people 18 to 80, run by Nanjing Medical University. It plans to enroll about 300 people at 8 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Aortic Aneurysm and Dissection.
Confirmed diagnosis of acute aortic dissection by contrast-enhanced Computed Tomography Angiography (CTA) or Magnetic Resonance Angiography (MRA);
Planned emergency surgical treatment (including open surgery and endovascular repair);
Aged 18-80 years old, regardless of gender;
Time from onset to hospital admission ≤ 72 hours;
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Ulinastatin and Thymalfasin; Ulinastatin
Registered summary
Aortic dissection has acute onset and high mortality, with immunoinflammatory response driving lesion progression. Current perioperative anti-inflammatory therapies are mostly empirical and poorly targeted, and AI-assisted typing lacks a complete clinical translation pathway. This study integrates multi-dimensional data to construct an AI immunoinflammatory subtyping system, enabling rapid subtyping and establishing a "subtyping-target-treatment" closed loop for emergency needs. The full summary is on the listing.
Where, as registered
No US site; China (8).
Not yet recruitingNCT07780721
Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer
Phase 2
The Affiliated Hospital of Putian University
About 31 people
Starts Aug 30, 2026 (estimated)
In plain words A Phase 2 study of thymosin Alpha-1 in people 18 to 80, run by The Affiliated Hospital of Putian University. It plans to enroll about 31 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Esophageal Cancer.
Has signed the written informed consent form and voluntarily participates in this study;
Aged 18-80 years, male or female;
Histopathologically or cytologically confirmed esophageal squamous cell carcinoma;
Clinical stage: cT1b-cT2N+M0 or cT3-cT4a any N M0;
12 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Adebrelimab; Thymalfasin; Chemotherapy
Registered summary
This is a prospective, single-arm, multicenter clinical study conducted in China. Patients with pathologically or cytologically confirmed resectable esophageal squamous cell carcinoma will be enrolled to explore the efficacy and safety of adebrelimab combined with thymalfasin and chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT06573398
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC
Phase 2
Ruijin Hospital
About 20 people
Starts Sep 1, 2024 (estimated)
In plain words A Phase 2 study of thymosin Alpha-1 in people 18 to 75, run by Ruijin Hospital. It plans to enroll about 20 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Carcinoma, Pancreatic Ductal.
Age ≥ 18 years, with ECOG score of 0 ~ 1;
Histologically or cytologically confirmed diagnosis of ductal adenocarcinoma of pancreas;
Classification as borderline resectable pancreatic cancer according to the NCCN Guidelines (2024 Edition);
Deemed suitable for neoadjuvant therapy following discussion by the MDT team of the study site;
12 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin
Registered summary
This is a prospective, single-center, single-arm, phase II clinical study. The primary purpose of the study was to evaluate the efficacy and safety of radiotherapy with sequential albumin-bound paclitaxel + Gemcitabine chemotherapy + anti-PD-1 monoclonal antibody and Thymalfasin for borderline resectable pancreatic cancer, and to explore clinical indicators related to efficacy, further guiding subsequent individualized precise treatment.